Tesamorelin is a synthetic peptide analog of growth hormone–releasing hormone (GHRH). It is designed to stimulate the pituitary gland to naturally increase secretion of growth hormone (GH), which subsequently raises insulin-like growth factor 1 (IGF-1) levels.
In clinical research, Tesamorelin has been shown to:
-
Reduce visceral adipose tissue (abdominal fat).
-
Support preservation of lean body mass.
-
Improve metabolic markers such as triglycerides and cholesterol.
-
Be studied for potential roles in neuroprotection and healthy aging.
Tesamorelin is most notably FDA-approved for the treatment of HIV-associated lipodystrophy. Its additional applications remain under research investigation only.